Evidence-Based Management of Adverse Events From Cancer Immunotherapy

In this downloadable slideset, review expert insights and recommendations from NCCN Guidelines on identification and management of immune-related adverse events associated with immune checkpoint inhibitor therapy.
John Thompson Headshot
John A. Thompson, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 4.73 MB
Released: May 7, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by an educational grant from
Bristol-Myers Squibb

Related Content

On-demand Clinical Care Options (CCO) Webcast on corneal toxicity in patients receiving antibody-drug conjugate therapy for the treatment of cancer

Asim V. Farooq, MD
Program Director
Sagar Lonial, MD Anthony Perissinotti, PharmD, BCOP
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: January 20, 2021 Expired: January 19, 2022

Downloadable slides with notes from pharmacist and nursing experts on maintenance avelumab, enfortumab vedotin and erdafitinib for urothelial carcinoma, from CCO

Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Released: January 11, 2021

Simplified treatment option resource for advanced urothelial carcinoma highlighting recently approved agents, from Clinical Care Options (CCO)

person default Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Released: January 7, 2021

CCO guide on signs and symptoms of potential AEs for your patients receiving erdafitinib or enfortumab vedotin

person default Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Released: January 6, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue